Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 69 publications
Circulating tumor DNA concentration at diagnosis is a modifiable prognostic factor for distant metastatic recurrence in patients with high-risk breast cancer receiving neoadjuvant therapy.
Journal: medRxiv : the preprint server for health sciences
Published: August 20, 2026
Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2-Negative Breast Cancer: The I-SPY2 Randomized Clinical Trial.
Journal: JAMA oncology
Published: July 30, 2026
Neoadjuvant Palbociclib Treatment Impacts Cell Cycle Progression of DCIS.
Journal: Cancers
Published: July 18, 2026
Multicenter Interspecialty Consensus on Experimental Oncology Drug-Related Ocular Adverse Event Reporting.
Journal: JAMA ophthalmology
Published: December 04, 2025
Telemedicine as a gateway to early-phase oncology trials: lessons from 14 000 patients and future directions for global access and equity.
Journal: The oncologist
Published: September 30, 2025
Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial.
Journal: JCO precision oncology
Published: June 17, 2025
Advances in Targeting HER2 across Cancer Subtypes: A Pan-Tumor Approach.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 04, 2025
Disparities in the Surgical Management of the Axilla by Self-Identified Race in the Multicenter Neoadjuvant I-SPY2 Trial.
Journal: Annals of surgical oncology
Published: May 05, 2025
Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors.
Journal: Nature communications
Published: April 02, 2025
Modulating Treatment Outcomes of Patients with Solid Tumors in Immunotherapy Trials: A Drug Interaction Analysis from a Phase I Unit.
Journal: Cancer research communications
Published: February 04, 2025
Human Epidermal Growth Factor Receptor 2 Alterations and Prognostic Implications in All Subtypes of Breast Cancers.
Journal: JCO precision oncology
Published: January 31, 2025
Human Epidermal Growth Factor Receptor 2 Loss following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 28, 2024
Last Updated: 09/26/2026